Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Unknown 3Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1

Conditions

Colorectal Neoplasms 492Pancreatic Neoplasms 387Carcinoma, Hepatocellular 261Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190Esophageal Neoplasms 157Neoplasms 139Carcinoma, Non-Small-Cell Lung 133Liver Neoplasms 129Neoplasm Metastasis 124Breast Neoplasms 102Cholangiocarcinoma 94Melanoma 85Ovarian Neoplasms 79Lung Neoplasms 72Squamous Cell Carcinoma of Head and Neck 57Carcinoma, Renal Cell 57Gastrointestinal Neoplasms 55Sarcoma 46Biliary Tract Neoplasms 39Prostatic Neoplasms 36Head and Neck Neoplasms 36Esophageal Squamous Cell Carcinoma 36Adenocarcinoma Of Esophagus 36Urinary Bladder Neoplasms 33Adenocarcinoma 33Uterine Cervical Neoplasms 31Triple Negative Breast Neoplasms 31Gastrointestinal Stromal Tumors 31

Interventions

danvatirsen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ascites × Gastrointestinal × Clear all
NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
1 enrolled 10 charts
GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡